Abrams Royal Compounding Pharmacy Recalls Products After Adverse Event

According to the Cleveland Plain Dealer, Abrams Royal Compounding Pharmacy, a Dallas-based pharmaceutical product supplier, is recalling all of its unexpired sterile products after an adverse patient event.

The US Food and Drug Administration (FDA) announced the recall earlier this month. The products include injectable medications, IVs, eye drops, pellet implants, nasal sprays, inhalation solutions and eye ointments, which were shipped nationwide to health care facilities, physicians and patients from June 17 to December 17, 2013.

A patient in California reportedly suffered an adverse event after coming into contact with an Abrams product.

Poor hygiene and inadequate employee training in compounding pharmacies can have deadly consequences. Between 2012 and 2013, 64 people died after receiving contaminated injectable back steroids from the produced by New England Compounding Company (NECC).

In the NECC case, investigators discovered frightening conditions in a pharmacy plant, which included the alleged growth of black mold. In addition, earlier this year 15 people in two Texas hospitals became ill with bacterial bloodstream infections from a different Texas compounding pharmacy.

Our defective drug attorneys at the law firm of ZK represent victims and the families of victims injured or killed because of defective drugs from compounding pharmacies. Contact us at 888-841-9623 for a free consultation.

Happy Holidays: The defective drug attorneys of Zoll & Kranz, LLC would like to wish everyone a safe 2014.

Source: http://www.cleveland.com/healthfit/index.ssf/2013/12/abrams_royal_compounding_pharm.html